Novartis Looks To Extend Top-Selling Cosentyx Into Juvenile Arthritis

Primary Endpoint Met In Phase III JUNIPERA Study

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.